Compare Neurocrine Biosciences Inc (NBIX) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wolfspeed Inc — how do they compare? Neurocrine Biosciences Inc trades at $140.75 (market cap $14.36B), while Wolfspeed Inc trades at $31.29 (market cap $1.64B). The key difference: Neurocrine Biosciences Inc is far larger — about 8.8× Wolfspeed Inc's market cap, and Wolfspeed Inc is more actively traded (22,772,687 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Wolfspeed Inc for 19 Days on average.
| NBIX | WOLF | |
|---|---|---|
Market Cap | $14.36B | $1.64B |
Volume | 1,237,180 | 22,772,687 |
Sector | Health | Technology |
52-Week High | $185.50 | $73.68 |
52-Week Low | $123.10 | $14.80 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | $14.37B | $2.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Wolfspeed (WOLF) trades at $31.23, down 0.45% on the day, with a bullish technical signal driven by moving averages. The company reported a significant net loss of -$1.61B in 2025, with negative gross and net profit margins, though 2026 projections show potential for a small profit. Recent news highlights expansion of its 200mm silicon carbide portfolio, positioning it in the growing AI infrastructure sector.
The outlook is mixed; analyst consensus is a Buy with a $54.32 price target, suggesting substantial upside, but high execution risk remains due to persistent losses and ongoing legal investigations. Revenue growth and achieving profitability are critical for stock performance, with the transition to 800-volt AI data centers being a potential catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
